Signals

Recent public signals

Crawlable detail links for recent public signal pages, so search engines can discover more than the live brief.

• FDA approves new treatments for rare diseases from Ultragenyx and Regeneron

  The FDA has granted accelerated approval to Ultragenyx's Genglycos, the first gene therapy for glycogen storage disease type Ia (GSDIa) in patients aged 8 and older, marking a milestone for this rare metabolic disorder.

• FDA grants accelerated approval to Replimune's melanoma drug after prior rejections

  After two previous rejections, Replimune's engineered viral immunotherapy Tudriqev has received accelerated FDA approval for treating advanced, treatment-resistant melanoma. The decision was influenced by an advisory panel that disputed the FDA scientists' earlier reservations, enabling a new treatment option for patients with limited alternatives. This approval marks a significant milestone for Replimune and the field of oncolytic viral therapies in oncology.

• GSK’s hepatitis B drug achieves functional cure in nearly one-fifth of patients in phase 3 trials

  GSK and Ionis Pharmaceuticals reported phase 3 trial results for bepirovirsen, showing nearly 20% of patients with chronic hepatitis B achieved a functional cure.

• FDA delays decision on AstraZeneca’s breast cancer drug camizestrant after negative advisory vote

  The FDA has delayed its decision on AstraZeneca’s camizestrant, a breast cancer treatment, after an advisory committee voted against its approval. The regulatory agency is now reviewing further analyses submitted post-vote, reflecting concerns about the inconclusive evidence for this novel therapy. This extension underscores the FDA’s cautious approach to new breast cancer drugs when clinical data remain uncertain.

• Parabilis files for IPO to advance peptide-based tumor therapies after Regeneron deal

  Parabilis Medicines has filed for an IPO to fund late-stage development of its peptide-based tumor therapies after securing a collaboration deal with Regeneron.

• FDA approves AstraZeneca’s new hypertension drug baxdrostat

  AstraZeneca has received FDA approval for baxdrostat, a novel aldosterone synthase inhibitor developed in partnership with CinCor Pharma to treat hypertension.

• Regeneron's LAG-3 inhibitor fails phase 3 melanoma trial, marking second late-stage setback

  Regeneron's phase 3 trial of its LAG-3 inhibitor fianlimab combined with Libtayo in melanoma failed to meet its primary endpoint, not significantly outperforming Keytruda. This unexpected result represents the company's second major late-stage clinical failure within a year and led to a sharp decline in market value.

• Biogen advances tau-targeting Alzheimer's drug despite phase 2 trial setback

  Biogen is moving forward with late-stage development of its tau-targeting Alzheimer's drug BIIB080 despite a phase 2 trial missing its primary endpoint.

• Regenxbio’s Duchenne gene therapy meets primary endpoint in pivotal phase 3 trial

  Regenxbio has achieved a significant milestone by meeting the primary endpoint in its pivotal phase 3 trial for Duchenne muscular dystrophy gene therapy.

• FDA commissioner Marty Makary resigns after turbulent tenure

  Marty Makary, M.D., has resigned as FDA commissioner, ending a brief and tumultuous period marked by leadership upheaval, political pressure, and public disputes with drugmakers. His departure leaves the agency with temporary directors in key roles and uncertainty about the future of newly implemented policies.

• Celcuity’s gedatolisib shows positive phase 3 results in breast cancer, advancing FDA filings

  Celcuity’s pan-PI3K/mTOR inhibitor gedatolisib has met the primary endpoint in the phase 3 Viktoria-1 trial for HR+ metastatic breast cancer, demonstrating significantly longer progression-free survival compared to Novartis’ Piqray in PIK3CA-mutant patients.

• UCB acquires Candid Therapeutics for $2 billion to expand autoimmune T-cell engager portfolio

  UCB is acquiring Candid Therapeutics for $2 billion upfront, gaining access to a portfolio of bispecific antibody drugs targeting autoimmune diseases.

• FDA approves Pfizer and Arvinas' novel breast cancer drug Veppanu

  Veppanu, developed by Arvinas and Pfizer, received early FDA approval as a first-in-class breast cancer treatment. This milestone expands therapeutic options for patients with certain breast cancers. However, Pfizer and Arvinas plan to partner with another company for commercialization, indicating ongoing strategic efforts post-approval.

• Summit Therapeutics shares fall after surprise interim miss in ivonescimab trial

  Summit Therapeutics experienced a sharp decline in share price following an unexpected interim analysis miss in its Harmoni-3 trial of ivonescimab, a PD-1xVEGF bispecific antibody.

• Avalyn Pharma raises $300 million in oversized IPO to advance inhaled respiratory drugs

  Avalyn Pharma has completed an oversized initial public offering, raising $300 million to fund the late-stage development of its inhaled reformulations of approved respiratory drugs. The biotech's successful IPO reflects strong investor interest in respiratory drug innovation and will enable Avalyn to advance clinical trials for these potentially improved therapies.

• AstraZeneca resumes $300 million UK investment after pricing dispute pause

  AstraZeneca has reversed its decision to freeze a $300 million investment program in the UK, restarting projects at two sites after a seven-month pause caused by frustrations over national drug pricing negotiations.

• Chiesi to acquire KalVista and its hereditary angioedema drug Ekterly in $1.9 billion deal

  Chiesi Group is expanding its rare disease portfolio by acquiring KalVista Pharmaceuticals for $1.9 billion. This deal includes KalVista's oral hereditary angioedema drug Ekterly, which is approaching its one-year mark since FDA approval. The acquisition underscores the pharmaceutical industry's increasing focus on innovative oral therapies for rare diseases like HAE and marks Chiesi's fifth biotech acquisition in a short period, signaling strategic growth in this sector.

• Eli Lilly acquires Ajax Therapeutics for next-generation myelofibrosis JAK inhibitor

  Eli Lilly continues its strategic expansion in biotech by acquiring Ajax Therapeutics for up to $2.3 billion. Ajax's clinical-stage type 2 JAK-2 inhibitor targets myelofibrosis, aiming to overcome the shortcomings of current JAK inhibitors. This acquisition strengthens Lilly's hematology pipeline and reflects the company's focus on next-generation targeted therapies for unmet medical needs.

• Intellia files for FDA approval after successful phase 3 trial of in vivo CRISPR therapy

  Intellia Therapeutics announced that its in vivo gene editing therapy, lonvoguran ziclumeran, met the primary endpoint in a phase 3 trial targeting hereditary angioedema.

• FDA approves first gene therapy for genetic hearing loss under priority voucher program

  The FDA has approved Otarmeni (lunsotogene parvec-cwha), developed by Regeneron, as the first-ever gene therapy to treat a rare inherited form of hearing loss.

• Merck deepens AI investment with $1 billion Google Cloud deal amid pharma industry shifts

  Merck is advancing its artificial intelligence capabilities through a $1 billion enterprise agreement with Google Cloud, signaling a strong commitment to AI-driven drug development despite ongoing industry challenges such as layoffs and mergers.

• Eli Lilly to acquire Kelonia Therapeutics in up to $7 billion deal for in vivo cell therapy

  Eli Lilly is expanding its in vivo cell therapy portfolio with the acquisition of Kelonia Therapeutics, a company developing a phase 1-stage CAR-T therapy targeting multiple myeloma. The deal, valued at up to $7 billion with $3.25 billion paid upfront, represents Lilly's second acquisition in this space this year. This move underscores Lilly's commitment to advancing innovative cancer treatments through early-stage cell therapy development.

• Trump orders FDA to fast-track reviews of psychedelic drugs for mental illness treatment

  President Donald Trump has directed the FDA to prioritize reviews of psychedelic drugs to expedite access to treatments for serious mental illnesses. This move aims to clear regulatory barriers and accelerate drug development in this emerging therapeutic area.

• OpenAI launches GPT-Rosalind AI to accelerate drug discovery and biology research

  OpenAI has unveiled GPT-Rosalind, an AI model tailored specifically for drug discovery and biology research. The launch comes shortly after OpenAI's partnership with Novo Nordisk, highlighting a strategic focus on biotech innovation. Multiple biotech firms have begun adopting GPT-Rosalind, reflecting growing industry interest in AI-driven tools to accelerate translational medicine and drug development.

• Travere wins FDA approval for Filspari in rare kidney disease FSGS

  Travere Therapeutics has received FDA approval for Filspari to treat focal segmental glomerulosclerosis (FSGS), marking a significant milestone in addressing this rare kidney disease.

• Eli Lilly acquires CrossBridge Bio to expand dual-payload ADC pipeline

  Eli Lilly has acquired Houston-based CrossBridge Bio in a deal worth up to $300 million to enhance its antibody-drug conjugate (ADC) portfolio.

• Revolution’s RAS inhibitor nearly doubles survival in phase 3 pancreatic cancer trial

  Revolution’s RAS inhibitor has demonstrated a significant survival benefit in a phase 3 trial for pancreatic cancer, a disease with historically poor outcomes. Analysts have described the results as a potential game changer, nearly doubling survival rates in this difficult-to-treat tumor type.

• Avalyn Pharma files IPO to fund phase 3 trials of inhaled lung disease drugs

  Coverage discusses speculative scenarios; treat as market chatter and see linked sources.

• Jeito Capital closes record $1.2 billion fund for European biopharma

  Jeito Capital has secured $1.2 billion in funding, the largest raise ever for an independent European biopharma-focused venture fund. This new capital will back 15 to 20 clinical-stage biopharma companies, highlighting strong investor confidence in European biotech innovation and positioning Jeito as a key player in advancing clinical-stage drug development across the region.

• Gilead acquires Tubulis to enhance oncology ADC pipeline with $5 billion deal

  Gilead Sciences has agreed to acquire Tubulis for $3.15 billion upfront plus up to $1.85 billion in milestone payments.

• Sanofi’s bispecific drug lunsekimig shows mixed phase 2 results in respiratory and eczema trials

  Sanofi's bispecific antibody lunsekimig, targeting TSLP and IL-13, demonstrated positive phase 2 clinical trial results in asthma and nasal polyps but failed to meet endpoints in a separate eczema study.

• Immunovant’s FcRn inhibitor fails phase 3 trials for thyroid eye disease

  Immunovant’s first-generation FcRn inhibitor failed two pivotal phase 3 clinical trials targeting thyroid eye disease, effectively ending prospects for the drug's commercialization.

• FDA approves Eli Lilly’s oral weight-loss pill Foundayo, intensifying competition with Novo Nordisk

  The FDA has approved Foundayo (orforglipron), Eli Lilly’s once-daily oral GLP-1 receptor agonist for weight loss, marking the second GLP-1 pill to reach the US market after Novo Nordisk’s Wegovy.

• United Therapeutics advances Tyvaso for idiopathic pulmonary fibrosis after second phase 3 success; Amgen gains EU nod for lung cancer BiTE

  United Therapeutics is preparing an FDA filing to expand Tyvaso's use following a second positive phase 3 trial in idiopathic pulmonary fibrosis (IPF), reinforcing its potential beyond pulmonary arterial hypertension.

• Kailera Therapeutics files for IPO to advance obesity drug pipeline

  Kailera Therapeutics, a biotech focused on obesity treatments, is advancing its late-stage drug candidates through a planned IPO in the US. After raising $1 billion in venture capital in 2025, the company seeks additional funding to accelerate clinical trials and development of its obesity drug portfolio. Led by Ron Renaud, Kailera aims to compete with established obesity drugs such as Wegovy and Zepbound, addressing a significant unmet medical need in the growing obesity market.

• AstraZeneca’s tozorakimab shows strong phase 3 results in COPD trials

  AstraZeneca’s tozorakimab, an IL-33 targeting drug for COPD, delivered unexpectedly strong phase 3 trial results, outperforming similar therapies that have struggled in this indication. The drug showed broad efficacy across COPD patient groups, suggesting it could address a significant unmet need beyond the reach of current treatments such as Dupixent. This breakthrough may reinvigorate the COPD drug class and pave the way for regulatory approvals and wider patient access.

• FDA approves Rocket's gene therapy Kresladi for rare immune disorder

  Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi (marnetegragene autotemcel), its first hematopoietic stem cell-based gene therapy, to treat children with severe leukocyte adhesion deficiency-1 (LAD-1).

• FDA approves Denali Therapeutics’ enzyme therapy for Hunter syndrome, breaking rare disease rejection streak

  Denali Therapeutics has received FDA approval for Avlayah, an enzyme replacement therapy targeting Hunter syndrome, a rare genetic lysosomal storage disorder. This approval ends a recent pattern of FDA rejections for rare disease therapies, which had drawn criticism from the biotech community. Industry observers describe Avlayah as a 'game-changer' that could improve treatment options for patients with this debilitating condition and reinvigorate confidence in rare disease drug development.

• Takeda plans major restructuring to fund drug launches and pipeline development

  Takeda is initiating a sweeping restructuring plan targeting $1.2 billion in cost savings through 2028 to finance upcoming drug launches and late-stage pipeline development. This strategic move under the new CEO focuses on operational streamlining and will involve substantial workforce reductions, particularly affecting the Cambridge, Massachusetts site and remote employees. The restructuring underscores Takeda's efforts to optimize resources for its future growth in pharmaceuticals.

• Merck to acquire Terns Pharmaceuticals for $6.7 billion to gain promising leukemia drug

  Merck's $6.7 billion all-cash acquisition of Terns Pharmaceuticals centers on a differentiated chronic myeloid leukemia treatment that could rival Novartis' Scemblix. The deal, reported as nearing completion, reflects Merck's strategic focus on oncology and hematology therapies. Analysts suggest the modest premium paid may attract competing offers, indicating high market interest in this promising asset. This acquisition exemplifies ongoing consolidation and investment in biotech innovation targeting leukemia.

• Pfizer and Valneva to seek approval for Lyme disease vaccine despite phase 3 trial missing primary endpoint

  Pfizer and Valneva reported that their phase 3 Lyme disease vaccine trial did not meet its primary endpoint, attributing the shortfall to fewer than expected Lyme disease cases during the study.

• FDA schedules public hearing to gather input on national priority voucher program

  The FDA has announced a public hearing on June 12 to solicit industry feedback on its National Priority Voucher program, launched last June. The program has enabled four ultra-rapid drug reviews so far but has faced criticism for its lack of transparency.

• Novartis acquires Synnovation’s PI3Kα breast cancer drug in multi-billion dollar deal

  Novartis has acquired a unit of privately held Synnovation Therapeutics for up to $3 billion, securing a promising PI3Kα inhibitor aimed at treating breast cancers driven by PIK3CA mutations.

• FDA expands approval of Rhythm Pharma's Imcivree to acquired hypothalamic obesity

  Rhythm Pharma's Imcivree has received FDA approval for acquired hypothalamic obesity, marking the first drug approved for this brain injury-driven form of obesity.

• FDA grants priority voucher for higher-dose Wegovy, speeding Novo Nordisk's approval

  Novo Nordisk has secured FDA approval for a higher dose of its obesity drug Wegovy, benefiting from a rare priority review voucher that accelerated clearance to just 54 days.

• AstraZeneca plans cell therapy manufacturing and innovation hub in Shanghai

  AstraZeneca announced plans to build a commercial cell therapy manufacturing base and an innovation center in Shanghai as part of its $15 billion investment commitment in China.

• Pfizer’s atirmociclib shows positive phase 2 results in second-line metastatic breast cancer

  Pfizer announced positive phase 2 results for atirmociclib, a CDK4-selective inhibitor, in second-line ER+ metastatic breast cancer.

• Structure Therapeutics reports best-in-class weight loss with oral GLP-1 candidate aleniglipron

  Structure Therapeutics announced that its oral GLP-1 drug candidate aleniglipron achieved a 16% weight loss in clinical testing, marking the highest efficacy reported for an oral GLP-1 treatment to date. The company is preparing to advance aleniglipron into phase 3 trials.

• FDA restarts review of Capricor’s Duchenne cell therapy as Xenon reports strong epilepsy results

  Xenon Pharmaceuticals saw its shares surge nearly 50% after reporting epilepsy trial results that exceeded Wall Street expectations.

• BioNTech founders to leave and launch new next-generation mRNA company

  BioNTech CEO Uğur Şahin and CMO/co-founder Özlem Türeci plan to depart the company by the end of the year to start a new venture focused on next-generation mRNA innovations.

• FDA approves leucovorin for rare cerebral folate deficiency but not for autism

  The FDA has approved Wellcovorin (leucovorin calcium) tablets for treating cerebral folate deficiency in patients with a confirmed folate receptor 1 gene variant (CFD-FOLR1).

• The FDA's newest draft guidance reinforces its previous commitment to streamlining biosimilar drug development by removing certain testing requirements for t...

  The U.S. Food and Drug Administration today announced another major step in its initiative to streamline the development of biosimilar medicines, which are like “generic” versions of biologic drugs.

• Vinay Prasad, controversial FDA leader, to again depart agency

  Vinay Prasad, the controversial director of the FDA's Center for Biologics Evaluation and Research, is set to leave the agency at the end of April. His tenure has been characterized by significant changes to vaccine guidelines and contentious drug rejections, leading to criticism from various advocates.

• Servier to build cancer drug pipeline with $2.5B purchase of Day One

  Servier snaps up cancer biotech Day One in $2.5bn deal Phil.Taylor Fri, 06/03/2026 - 15:03.

• Roche and Zealand's obesity drug results disappoint

  The recent performance of Roche and Zealand's obesity drug has raised concerns among investors and analysts. The amylin-targeting medication, which is central to a multibillion-dollar partnership between the two companies, has shown less weight loss efficacy than anticipated, leading to questions about its market differentiation. This disappointing outcome has resulted in a decline in shares for both companies, as stakeholders reassess the drug's potential in a competitive landscape.

• FDA Commissioner Marty Makary, M.D., called J&J’s Tecvayli-Darzalex phase 3 showing the “most impressive second-line myeloma trial results in history.”

  J&J's Tecvayli claims third national priority FDA approval Phil.Taylor Fri, 06/03/2026 - 10:59.

• FDA Places Partial Hold on PepGen's Muscular Dystrophy Drug Trial

  The FDA has placed a partial clinical hold on PepGen's phase 2 trial for its muscular dystrophy drug, creating uncertainty in the drug's development timeline. Analysts attribute this unexpected pause to the agency's staffing challenges, raising concerns about the impact on ongoing clinical programs.

• FDA intensifies scrutiny of compounded GLP-1 drugs and novo nordisk ads

  The FDA has ramped up its crackdown on compounded GLP-1 drugs, issuing 30 warning letters to pharmacies. Novo Nordisk faces regulatory scrutiny over its GLP-1 ads, while Intellia is set to restart a heart disease trial.

• Sanofi acquires sino biopharm’s JAK/ROCK inhibitor for $1.53B

  Sanofi has made a significant move in the biotech sector by acquiring global rights to a first-in-class JAK/ROCK inhibitor from Sino Biopharmaceutical for $1.53 billion. This novel drug is expected to enhance Sanofi's offerings in both hematology and immunology, targeting conditions such as myelofibrosis and chronic graft-versus-host disease (cGVHD). The deal underscores Sanofi's commitment to expanding its pipeline with innovative therapies.

• Moderna will pay $950 million upfront—and no future royalties—to settle patent litigation over its mRNA-based vaccine Spikevax. The case was brought by Roiva...

  Moderna agrees $950m settlement of mRNA jab litigation Phil.Taylor Wed, 04/03/2026 - 13:19.

• Biotech companies face layoffs after regulatory setbacks

  Disc Medicine and Theravance Biopharma are laying off employees due to recent regulatory challenges, reflecting the financial strain on biotech firms.

• UniQure faces major setback as FDA rejects gene therapy data package

  uniQure's AMT-130 gene therapy for Huntington's disease has encountered a significant regulatory hurdle as the FDA has rejected its data package. This decision has led to a dramatic 40% drop in the company's shares. The FDA now requires uniQure to conduct a new sham surgery-controlled trial before any approval can be considered, which could further delay access to this potential treatment for patients suffering from Huntington's disease.

• Roche's fenebrutinib achieves phase 3 success amid safety concerns

  Roche's fenebrutinib has successfully met its primary endpoint in a second Phase 3 study for relapsing multiple sclerosis. However, the drug's approval may be jeopardized by safety concerns, including a higher mortality rate compared to the control group.

• Eli lilly partners with nvidia to innovate pharma with AI

  Eli Lilly's collaboration with Nvidia aims to innovate drug development using AI technology. However, experts express skepticism about AI's effectiveness in speeding up clinical trials, emphasizing the need for realistic expectations.

• While the FDA has flip-flopped on whether to review Moderna’s combination influenza/COVID-19 vaccine, it’s full speed ahead for the mRNA shot in Europe, with...

  Moderna closes on EU approval for combined flu/COVID jab Phil.Taylor Fri, 27/02/2026 - 12:52.

• Senate hearing critiques fda's rare disease review process

  In a recent Senate hearing, a panel comprising physicians, biotech leaders, and patient advocates criticized the FDA's processes, particularly regarding its impact on innovation in the field of rare diseases. The discussion highlighted concerns over the agency's bureaucracy and its implications for drug development and approval timelines. Lawmakers are increasingly pressing the FDA to improve its record on rare diseases, reflecting a growing urgency to enhance the regulatory environment for biotech advancements.

• Bristol myers squibb's ADC hits key survival endpoints in phase 3 trial

  Bristol Myers Squibb's ADC has achieved dual primary survival endpoints in a phase 3 breast cancer trial in China, validating its $800 million investment. The drug, in-licensed from Systimmune, is crucial for the company's future growth and is undergoing further trials in TNBC.

• Eli lilly's orforglipron outperforms competitors in diabetes trials

  Eli Lilly's orforglipron has outperformed Rybelsus and Wegovy in recent trials, showing significant weight loss and blood sugar reduction. This oral medication could provide a non-injection alternative for diabetes and obesity treatment.

• Surge in licensing deal values between western and chinese biopharma

  The landscape of biotech licensing deals between Western biopharma companies and their Chinese counterparts has undergone a significant transformation. Recent data reveals that the average upfront value for these deals has surged dramatically, reflecting a shift in the market dynamics.

• Fierce Pharma: 15 States sue HHS over changes to childhood vaccine schedule

  A coalition of 15 states has initiated legal action against the U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC). The lawsuit aims to reverse recent changes to the childhood vaccine schedule, which the states argue were made unlawfully. The abrupt overhaul of the immunization schedule has raised concerns among these states, prompting them to challenge the federal government's actions in court.

• FDA unveils draft guidance for personalized therapies in ultra-rare diseases

  The FDA has recently unveiled a series of draft guidance documents aimed at accelerating the development and approval of personalized therapies for ultra-rare diseases. This initiative is part of a broader effort to provide a regulatory framework that supports the creation of individualized treatments, particularly when traditional randomized controlled trials are not feasible due to limited patient populations.

• Novo’s next-gen obesity shot fails to match lilly drug in head-to-head study

  Novo Nordisk's latest obesity treatment, CagriSema, has faced significant setbacks in clinical trials, failing to outperform Eli Lilly's Zepbound in a head-to-head study. This disappointing outcome has led to a sharp decline in Novo Nordisk's stock price, reflecting investor concerns about the future of its obesity drug portfolio.

• Gilead buys cell therapy partner arcellx for up to $7.8bn

  Gilead has acquired Arcellx for up to $7.8 billion, aiming to enhance its cell therapy portfolio, particularly for multiple myeloma. This acquisition focuses on a CAR-T cell therapy that is nearing regulatory approval, which Gilead's CEO believes will become a foundational treatment for this type of blood cancer. The move is seen as a strategic effort to revitalize Gilead's cell therapy business amid a competitive landscape.

• FDA will now default to one clinical trial for drug applications

  The FDA has announced a new guideline stating that it will now default to one pivotal clinical trial for drug approvals, aiming to reduce costs and speed up development while ensuring safety standards are met.

• FDA starts/accepts review of BMS “celmod” in multiple myeloma as other decisions diverge

  A near-term U.S. regulatory catalyst emerged as the FDA began/accepted review of Bristol Myers Squibb’s “celmod” protein degrader in multiple myeloma, while a broader industry roundup in the same news cycle paired that milestone with a rare-disease regulatory setback for Disc and a separate European approval for Cytokinetics’ heart-disease therapy.

• Lilly to pay CSL $100M upfront to license phase 3-stage IL-6 antibody

  Eli Lilly is expanding its immunology pipeline via a licensing deal for a Phase 3-stage IL-6-targeting monoclonal antibody from CSL. The agreement includes a $100 million upfront payment, while CSL keeps rights in an end-stage kidney disease indication that is already in Phase 3, and Lilly evaluates other potential uses for the antibody.

• FDA reverses course and proceeds with review of moderna flu vaccine filing

  Reports from Fierce Biotech, pharmaphorum, and The Economic Times say the FDA has reversed course and will proceed with reviewing Moderna’s influenza vaccine submission, with coverage framing the move as a rapid rethink/u-turn by the agency.

• FDA declines to accept moderna mRNA flu vaccine filing; FDA cites trial-design concerns

  The FDA refused to accept Moderna’s application for an mRNA influenza vaccine for review. Moderna criticized the decision as inconsistent with prior FDA communications and established flu-shot guidance.

• Moderna says FDA refused to file its mRNA flu shot application, citing trial-design concer

  Moderna says the FDA has declined to review (refused to file) its application for an experimental mRNA flu shot, triggering a public dispute over what the agency required for the submission. Coverage highlights Moderna’s objection to the FDA’s rationale and points to trial-design concerns—specifically the control arm used in the study—as a key issue raised in the company’s account of the refusal-to-file decision.

• FDA rejects regenxbio’s hunter syndrome gene therapy

  BioPharma Dive, Fierce Biotech, and pharmaphorum report that the FDA has rejected Regenxbio’s gene therapy/treatment for Hunter syndrome, characterizing the decision as a setback for the program and another negative development for gene therapy.

• Generate:biomedicines moves toward IPO as agomab and SpyGlass price offerings

  A fresh burst of biotech IPO activity is taking shape. Multiple outlets report that Flagship-backed Generate:Biomedicines has moved toward the public markets, while a separate update highlights two other biotechs—Agomab and SpyGlass—successfully pricing offerings in what was described as the busiest week for new biotech stock issuances in a year.

• Novo’s CagriSema tops semaglutide in phase 3 diabetes; pfizer’s monthly GLP-1 draws mixed

  Coverage discusses speculative scenarios around ~$10B; treat as market chatter and see linked sources.

• FDA rejects AstraZeneca’s self-injected saphnelo; FDA launches ‘PreCheck’ program

  Multiple outlets report FDA rejected AstraZeneca’s application for a subcutaneous, self-administered version of lupus treatment Saphnelo delivered via a prefilled pen, which was positioned as an alternative to in-office infusions every four weeks.

• Amgen terminates kyowa kirin collaboration on rocatinlimab

  Amgen is pulling back from a partnered autoimmune/atopic dermatitis program by terminating its collaboration with Kyowa Kirin on rocatinlimab, an anti-OX40 antibody. The move highlights how late-stage development and partnership economics can shift, even for previously high-profile pipeline assets.

• Biopharma’s 2026 setup: rebound signals and a shift to capability-led m&a

  As biopharma M&A activity ramps back up, strategy is shifting to no longer focus on securing the next blockbuster drug, but instead to ink deals that build out capabilities across the entire drug development and commercialization process.

• Sanofi flags tougher vaccine backdrop as mRNA seasonal flu program is put on ice

  Sanofi’s latest vaccines readout combines softer near-term commercial expectations with a reported pipeline reset.

• Tenpoint wins FDA approval for yuvezzi presbyopia eye drop; launch funding cited

  Tenpoint Therapeutics has secured an FDA approval for Yuvezzi, positioning the presbyopia eye drop for near-term U.S. commercialization. Coverage across outlets links the regulatory milestone to immediate launch planning and a stated $235 million raise intended to support marketing/launch execution, while also framing Yuvezzi as competing against existing presbyopia options (including AbbVie-referenced treatments).

• FDA lifts one of two clinical holds on intellia CRISPR TTR program

  Regulators partially eased restrictions on Intellia’s CRISPR program in transthyretin amyloidosis after serious safety concerns prompted pauses in two late-stage studies. The update allows one Phase 3 study to resume while another trial remains on hold, with the company describing added safeguards in response to the reported death and liver event.

• Roche obesity coverage centers on new data and phase 3 timing

  A pair of trade reports highlight Roche’s obesity-program momentum. Fierce Biotech points to a dual GLP-1/GIP receptor agonist associated with 22.5% weight loss at 48 weeks and says Roche is moving the asset into phase 3 studies this quarter.

• Sanofi presses ahead with amlitelimab filings after mixed phase 3 eczema data

  BioPharma Dive and Fierce Biotech report that Sanofi disclosed mixed Phase 3 results for amlitelimab in atopic dermatitis/eczema.

• Corxel raises $287M series d to advance oral GLP-1 obesity pill and phase 2 plans

  A fresh Series D for Corxel Pharmaceuticals is being positioned as a signal that large checks are still available for obesity assets, particularly programs aiming to differentiate via oral GLP-1 delivery and near-term clinical advancement.

• FDA draft guidance spotlights MRD and complete response for myeloma accelerated approval

  U.S. regulators are signaling a potential shift in what evidence may support faster pathways in multiple myeloma. Recent coverage centers on an FDA draft guidance that discusses using minimal residual disease (MRD) and complete response as potential supports for accelerated approval, alongside commentary that this could, in certain cases, enable clearance based on eliminating tumor cells.

• Caldera launches with $112.5M to develop china-licensed dual-targeting IBD drug

  Caldera emerged with $112.5M in combined Series A financing to support development of an inflammatory bowel disease program licensed from China. The company’s lead asset is described as a dual-targeting (bispecific) immune medicine aimed at two popular targets, positioned as a potential therapeutic advance for IBD.

• AbbVie commits $650m upfront to RemeGen, stepping into pd-1xvegf bispecific competition

  AbbVie is moving from stated interest to concrete action in the increasingly competitive PD-1xVEGF bispecific arena. Across multiple reports, the common thread is a $650 million upfront payment to China’s RemeGen for a dual-targeting immunotherapy—framing the deal as AbbVie’s entry into a “sweepstakes”/battle for this class of oncology assets.

• Insmed spotlights brinsupri’s first full-quarter sales beat ahead of JPM week

  Insmed’s Brinsupri posted a first full quarter on the market that exceeded consensus/Wall Street expectations, leading the company to share early launch numbers ahead of the J.P. Morgan Healthcare Conference news flow.

• Aktis’ $318M IPO opens 2026 biotech listings with an upsized deal

  Aktis completed a $318M IPO that both outlets describe as 2026’s first biotech IPO, with Fierce Biotech highlighting that the offering was upsized and exceeded the company’s expectations.

• Big early-2026 rounds back parabilis’ cancer push and diagonal’s clustering antibodies

  Early 2026 opened with two outsized private financings tied to near-term clinical ambitions. Parabilis disclosed a $305M Series F to back a novel cancer drug effort and fund a pivotal push for a potential first-in-class program, amid what BioPharma Dive described as a broader VC funding blitz.

• EpiBiologics lands $107M series b to advance protein-degrading cancer drug

  A single financing milestone is drawing attention to targeted protein degradation in cancer: EpiBiologics disclosed a $107M Series B to advance its protein-degrading oncology program, with coverage emphasizing both the size of the round and the profile of participating venture backers.

• Arrowhead’s early obesity gene-silencing data becomes a focal signal

  Arrowhead disclosed early-phase results for two gene-silencing obesity candidates, with preliminary evidence suggesting the molecules help people shed fat.

• GSK and ionis tee up bepirovirsen filings after phase 3 hepatitis b success

  GSK and Ionis said their RNA-based chronic hepatitis B candidate bepirovirsen succeeded in phase 3 studies and that global regulatory filings are planned. Coverage frames the program as pursuing a “functional cure,” while noting that detailed results were not provided in at least one report.

• GSK and ionis cite phase 3 success for bepirovirsen, teeing up filings

  GSK and Ionis said their RNA-based hepatitis B candidate bepirovirsen succeeded in Phase 3 studies, framing the program as a potential “functional cure” approach for chronic infection.

• FDA declines corcept drug; FierceBiotech also cites sanofi rejection

  Reports over the past day highlight FDA non-approvals affecting Corcept Therapeutics, with pharmaphorum focusing on the agency declining to approve Corcept's rare disorder drug. FierceBiotech frames the news as unwanted holiday-period developments, citing FDA rejections for both Corcept and Sanofi drug applications.